Cold weather, dry air, an overactive immune system or our modern lifestyle. The causes may vary, but an increasing number of ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Over the next 10 years, GlobalData has predicted that Dupixent will remain the most prescribed biologic therapy for atopic dermatitis, with global sales of $5.3 billion in 2027. The market ...

“While atopic dermatitis is a competitive and challenging ... “Rezpegaldesleukin has the potential to be highly disruptive in the biologic treatment landscape for AD as demonstrated by the ...

Atopic dermatitis, a chronic inflammatory skin rash ... These include an injectable biologic medication derived from natural sources and a new non-steroidal topical cream. Additionally, a ...

The global atopic dermatitis treatment market is on the cusp of remarkable expansion, with projections indicating a surge in ...

Therapeutics announced that the U.S. FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and ...